FDMT Net Debt from 2010 to 2025

FDMT Stock

USD 4.58 0.10 2.14%

4D Molecular Net Debt yearly trend continues to be comparatively stable with very little volatility. Net Debt will likely drop to about -221.5 M in 2025. Net Debt is the total debt of 4D Molecular Therapeutics minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2018-12-31

Previous Quarter

-175.4 M

Current Value

-162.7 M

Quarterly Volatility

87.2 M

Covid

Check 4D Molecular financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among 4D Molecular's main balance sheet or income statement drivers, such as Net Interest Income of 11.1 M, Interest Income of 11.1 M or Depreciation And Amortization of 4.2 M, as well as many indicators such as Price To Sales Ratio of 32.71, Dividend Yield of 0.0 or PTB Ratio of 2.43. FDMT financial statements analysis is a perfect complement when working with 4D Molecular Valuation or Volatility modules.

Check out the analysis of 4D Molecular Correlation against competitors.

Latest 4D Molecular's Net Debt Growth Pattern

Below is the plot of the Net Debt of 4D Molecular Therapeutics over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. 4D Molecular's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in 4D Molecular's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

FDMT Net Debt Regression Statistics

	Arithmetic Mean	(111,088,204)
	Geometric Mean	64,402,206
	Coefficient Of Variation	(96.82)
	Mean Deviation	97,333,630
	Median	(23,850,000)
	Standard Deviation	107,556,862
	Sample Variance	11568.5T
	Range	275.1M
	R-Value	(0.82)
	Mean Square Error	3979.2T
	R-Squared	0.68
	Significance	0.000087
	Slope	(18,615,206)
	Total Sum of Squares	173527.2T

FDMT Net Debt History

	2025	-221.5 M
	2024	-211 M
	2023	-234.4 M
	2022	-202.5 M
	2021	-299 M
	2020	-276.7 M
	2019	-49.7 M

Other Fundumenentals of 4D Molecular Therapeutics

Net Debt To E B I T D A

4D Molecular Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Capital Stock	Capital Surpluse	Deferred Long Term Liab
Total Assets		0.39	0.95	-0.65	-0.96	-0.89	0.94	0.32	0.32	0.94	1.0	0.99	0.83	0.97	0.87	0.97	0.86	0.88
Total Stockholder Equity	0.39		0.38	-0.33	-0.35	-0.48	0.19	0.35	-0.38	0.5	0.41	0.46	0.14	0.49	0.27	0.51	0.35	0.28
Net Tangible Assets	0.95	0.38		-0.67	-0.96	-0.87	0.88	0.21	0.31	0.99	0.95	0.93	0.79	0.91	0.89	0.92	0.83	0.85
Current Deferred Revenue	-0.65	-0.33	-0.67		0.54	0.87	-0.71	0.19	-0.02	-0.75	-0.61	-0.62	-0.63	-0.72	-0.86	-0.73	-0.92	-0.91
Net Debt	-0.96	-0.35	-0.96	0.54		0.82	-0.89	-0.38	-0.39	-0.94	-0.97	-0.95	-0.79	-0.88	-0.83	-0.89	-0.74	-0.77
Retained Earnings	-0.89	-0.48	-0.87	0.87	0.82		-0.87	-0.23	-0.05	-0.92	-0.87	-0.88	-0.86	-0.92	-0.92	-0.93	-0.94	-0.93
Accounts Payable	0.94	0.19	0.88	-0.71	-0.89	-0.87		0.14	0.49	0.88	0.93	0.89	0.86	0.89	0.94	0.89	0.9	0.93
Net Receivables	0.32	0.35	0.21	0.19	-0.38	-0.23	0.14		-0.27	0.21	0.35	0.41	0.39	0.28	-0.02	0.28	0.01	-0.02
Total Liab	0.32	-0.38	0.31	-0.02	-0.39	-0.05	0.49	-0.27		0.23	0.32	0.22	0.12	0.13	0.38	0.13	0.18	0.27
Net Invested Capital	0.94	0.5	0.99	-0.75	-0.94	-0.92	0.88	0.21	0.23		0.94	0.94	0.78	0.93	0.91	0.94	0.88	0.88
Total Current Assets	1.0	0.41	0.95	-0.61	-0.97	-0.87	0.93	0.35	0.32	0.94		0.99	0.82	0.96	0.85	0.96	0.83	0.85
Net Working Capital	0.99	0.46	0.93	-0.62	-0.95	-0.88	0.89	0.41	0.22	0.94	0.99		0.83	0.97	0.82	0.97	0.83	0.84
Short Term Debt	0.83	0.14	0.79	-0.63	-0.79	-0.86	0.86	0.39	0.12	0.78	0.82	0.83		0.83	0.8	0.83	0.81	0.81
Common Stock	0.97	0.49	0.91	-0.72	-0.88	-0.92	0.89	0.28	0.13	0.93	0.96	0.97	0.83		0.84	1.0	0.9	0.89
Property Plant Equipment	0.87	0.27	0.89	-0.86	-0.83	-0.92	0.94	-0.02	0.38	0.91	0.85	0.82	0.8	0.84		0.86	0.95	0.97
Capital Stock	0.97	0.51	0.92	-0.73	-0.89	-0.93	0.89	0.28	0.13	0.94	0.96	0.97	0.83	1.0	0.86		0.9	0.9
Capital Surpluse	0.86	0.35	0.83	-0.92	-0.74	-0.94	0.9	0.01	0.18	0.88	0.83	0.83	0.81	0.9	0.95	0.9		0.99
Deferred Long Term Liab	0.88	0.28	0.85	-0.91	-0.77	-0.93	0.93	-0.02	0.27	0.88	0.85	0.84	0.81	0.89	0.97	0.9	0.99

Click cells to compare fundamentals

About 4D Molecular Financial Statements

4D Molecular shareholders use historical fundamental indicators, such as Net Debt, to determine how well the company is positioned to perform in the future. Although 4D Molecular investors may analyze each financial statement separately, they are all interrelated. The changes in 4D Molecular's assets and liabilities, for example, are also reflected in the revenues and expenses on on 4D Molecular's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Net Debt	-211 M	-221.5 M
Net Debt To EBITDA	2.52	4.14

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for FDMT Stock Analysis

When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

FDMT Net Debt from 2010 to 2025

Latest 4D Molecular's Net Debt Growth Pattern

FDMT Net Debt Regression Statistics

FDMT Net Debt History

Other Fundumenentals of 4D Molecular Therapeutics

4D Molecular Net Debt component correlations

About 4D Molecular Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for FDMT Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY